Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that the study for the prevention and treatment of heart failure in dogs has been completed within the projected timeline.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/06/QGC_PR_QGC101-DOGS_20150629_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
